Purchase this article with an account.
Maximilian Schultheiss, Sven Schnichels, Eva-Maria Konrad, Karl-Ulrich Bartz-Schmidt, Grit Zahn, Patrizia Caldirola, Mario G Fsadni, Ninus Caram-Lelham, Martin Stephan Spitzer; Evaluation of the α5β1-integrin-inhibitor CLT-28643 in a trabeculectomy rabbit model. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3206.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Bleb failure after glaucoma filtering surgery (GFS) is mainly caused by wound healing and scarring with myofibroblasts playing a crucial role in this process. There is still a high medical need for better tolerated therapeutics than the currently used Mitomycin-C (MMC). α5β1-integrin plays a pivotal role in angiogenesis, inflammation and the activation of residing fibroblasts to myofibroblasts. CLT-28643 is an integrin-inhibitor targeting α5β1-integrin, and can be expected to inhibit scarring after GFS thereby enhancing bleb survival. This is the first study investigating the effect of CLT-28643 in GFS.
We conducted a double-blinded trabeculectomy-study with 24 rabbits. The right eyes were divided in three groups: 8 eyes received intraoperative MMC (sponge application, 0.04%, for 2 minutes) and placebo eye drops postoperatively (A); 8 eye received subconjunctival CLT-28643 intraoperatively and placebo eye drops postoperatively (B); and in 8 eyes CLT-28643 was applied intraoperatively and as eye drops postoperatively 4 times a day (C). Trabeculectomy was performed on the left eyes of 12 rabbits without any adjunctive treatment (D) and 12 left eye were not operated (E). Clinical assessment included IOP-measurement by Schiötz tonometry, slit lamp examination (bleb survival and Würzburg bleb score) and photographs of the blebs. Four weeks after trabeculectomy the rabbits were sacrificed and processed for histology.
CLT-28643 treatment (group B and C) compared to group D resulted in a significantly prolonged bleb survival and a better bleb score. IOP was significantly lowered in all trabeculectomy groups. IOP and bleb survival were comparable for CLT28643 and MMC treated groups and superior to vehicle treated control eyes. Clinically and histologically CLT-28643 was non-toxic and very well tolerated.
The data of this pilot study suggest that the integrin-inhibitor CLT-28643 may improve the outcome of trabeculectomy.
This PDF is available to Subscribers Only